Strikingly, the use of 78c led to a selective decrease in CD38+/CD43hi and CD43hi/galectin-1+ CLL populations upon increasing concentrations of inhibitor (Figures 3D and 3E), indicative of CD45 activity regulation by CD38. Here, PTPRC is linked to B-cell chronic lymphocytic leukemia.